{
    "clinical_study": {
        "@rank": "68632", 
        "arm_group": {
            "arm_group_label": "Neurostimulation for chronic pain", 
            "arm_group_type": "Experimental", 
            "description": "Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to investigate patient satisfaction with treatment\n      using a new implantable neurostimulation system for chronic pain of the trunk and/or limbs."
        }, 
        "brief_title": "Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Pain", 
        "condition_browse": {
            "mesh_term": "Pain, Intractable"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic intractable pain of the trunk and/or limbs\n\n          -  Documented history of trunk and/or limb pain of at least 180 days\n\n          -  Overall pain intensity of  at least 5 on a 0-10 numerical rating scale (OPI-NRS-11)\n             over the past 180 days based on subject recall\n\n          -  Pass study site's routine psychological/psychiatric evaluation within 180 days before\n             signing the informed consent\n\n          -  Subject is willing and able to comply with all protocol-required follow-up\n             evaluations\n\n          -  18 years of age or older when written informed consent is obtained\n\n          -  Subject signs informed consent\n\n        Exclusion Criteria:\n\n          -  Unable to operate the Precision Spectra\u2122 System either by self or with a caregiver\n\n          -  Primary source of pain is cancer-related, pelvic, visceral, anginal or migraine\n\n          -  Overall pain intensity of always 10 on a 0-10 numerical rating scale (OPI-NRS-11)\n             over the past 180 days based on subject recall\n\n          -  Is a high surgical risk\n\n          -  Currently on any anticoagulant medications that cannot be discontinued during\n             perioperative period\n\n          -  Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s) and/or\n             the Precision Spectra IPG\n\n          -  Subject is participating (or intends to participate) in another investigational drug\n             or device clinical trial that may influence the data that will be collected for this\n             study\n\n          -  Subjects already implanted with an active implantable device(s) to treat their pain\n             (IPGs, implantable drug pumps, etc) or pacemaker or Implantable Cardiac Defibrillator\n\n          -  Patient is a woman who is pregnant (a urine pregnancy test must be performed within 7\n             days prior to the stimulation trial procedure in women of child-bearing potential) or\n             nursing or intends to become pregnant during the course of the trial.\n\n          -  Failed to achieve satisfactory relief during the stimulation trial phase"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665040", 
            "org_study_id": "A5004"
        }, 
        "intervention": {
            "arm_group_label": "Neurostimulation for chronic pain", 
            "description": "Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.\nTreatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan.", 
            "intervention_name": "Neurostimulation device implantation", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "neurostimulation", 
            "spinal cord stimulation", 
            "peripheral nerve stimulation"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria"
                }, 
                "name": "Metro Spinal Clinic"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Precision Spectra\u2122 Neurostimulator System for the Treatment of Chronic Intractable Pain of the Trunk and/or Limbs", 
        "overall_contact": {
            "email": "Nic.VanDyck@bsci.com", 
            "last_name": "Nic Van Dyck", 
            "phone": "31-433568328"
        }, 
        "overall_contact_backup": {
            "email": "Diane.Bowers@bsci.com", 
            "last_name": "Diane Bowers", 
            "phone": "6619494175"
        }, 
        "overall_official": {
            "affiliation": "Metro Spinal Clinic", 
            "last_name": "Paul Verrills, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: National Health and Medical Research Council", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "First of 2 co-primary endpoints.  It is measured on a 7-point choice of degree of satisfaction scale.", 
                "measure": "Patient satisfaction with treatment", 
                "safety_issue": "No", 
                "time_frame": "90-days post permanent implantation"
            }, 
            {
                "description": "Second of 2 co-primary endpoints.  It is measured on a 7-point choice of degree of satisfaction scale.", 
                "measure": "Patient satisfaction with treatment", 
                "safety_issue": "No", 
                "time_frame": "365 days post permanent implantation"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665040"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Collected on a 7-point choice of degree of satisfaction scale.", 
                "measure": "Patient satisfaction with treatment", 
                "safety_issue": "No", 
                "time_frame": "180-days post permanent implantation"
            }, 
            {
                "description": "Global Impression of Change (GIC) will be assessed by patients, investigators and caregivers. GIC is a comparison to baseline and will be evaluated by rating the global impression of change using a seven-point scale:  (\"very much improved\" to \"marked worsening\")", 
                "measure": "Global impression of change", 
                "safety_issue": "No", 
                "time_frame": "180-days post permanent implantation"
            }, 
            {
                "description": "Subjects will rate their overall pain on a 0-10 numerical rating scale.", 
                "measure": "Overall pain intensity", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 365-days post permanent implantation"
            }, 
            {
                "description": "A \"responder\" is defined as a subject who reports \u226550% reduction in baseline pain.", 
                "measure": "Pain relief responder rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 365-days post permanent implantation"
            }, 
            {
                "description": "Disability will be assessed using the Oswestry Disability Index v2.1a", 
                "measure": "Disability", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 365-days post permanent implantation"
            }, 
            {
                "measure": "Global impression of change", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 365 days post permanent implantation"
            }, 
            {
                "measure": "Pain-related medication use", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 365 days post permanent implantation"
            }, 
            {
                "description": "Overlap will be assessed using subject-completed drawings of pain and neurostimulation-induced paresthesia (tingling)", 
                "measure": "Percentage overlap of painful areas with stimulation-induced paresthesia (drawings)", 
                "safety_issue": "No", 
                "time_frame": "From 90-days through 365-days post permanent implantation"
            }, 
            {
                "description": "Overlap will be assessed by subject estimation", 
                "measure": "Percentage overlap of painful areas with stimulation-induced paresthesias (verbal)", 
                "safety_issue": "No", 
                "time_frame": "From 90-days through 365 days post permanent implantation"
            }, 
            {
                "description": "Subjects who end up utilizing the full capacity of the implantable system will compare treatment from baseline through 90-days post permanent implantation with treatment from 90-days through 365-days post permanent implantation.", 
                "measure": "Patient treatment preference", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 365-days post permanent implantation"
            }
        ], 
        "source": "Boston Scientific Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Scientific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}